Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ZYME Zymeworks Inc
- Stocks
- Healthcare
- NYSE: ZYME
Price (delayed)
$12.41
Market cap
$864.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$807M
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
Highlights
Zymeworks's revenue has soared by 85% YoY and by 22% from the previous quarter
Zymeworks's gross profit has surged by 85% YoY and by 22% QoQ
The quick ratio has increased by 39% since the previous quarter but it has declined by 33% year-on-year
The company's equity fell by 26% YoY and by 4.1% QoQ
Key stats
What are the main financial stats of ZYME
Market
Valuations
Earnings
Shares outstanding
69.68M
Market cap
$864.77M
Enterprise value
$807M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.66
Price to sales (P/S)
9.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.64
Revenue
$93.38M
Gross profit
$93.38M
Operating income
-$124.92M
Net income
-$113.68M
EBIT
-$107.17M
EBITDA
-$94.99M
Free cash flow
-$77.6M
Per share
Balance sheet
Liquidity
EPS
-$1.5
EPS diluted
-$1.5
Free cash flow per share
-$1.03
Book value per share
$4.67
Revenue per share
$1.24
TBVPS
$5.46
Total assets
$425.52M
Total liabilities
$100.56M
Debt
$18.43M
Equity
$324.97M
Working capital
$241.36M
Debt to equity
0.06
Current ratio
4.71
Quick ratio
4.45
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
-101.7%
Gross margin
100%
Net margin
-121.7%
Operating margin
-133.8%
Return on assets
-24%
Return on equity
-31.6%
Return on invested capital
-33.7%
Return on capital employed
-29.7%
Return on sales
-114.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYME stock price
How has the Zymeworks stock price performed over time
Intraday
-1.12%
1 week
-3.2%
1 month
8.57%
1 year
44.13%
YTD
-15.23%
QTD
-1.12%
Financial performance
How have Zymeworks's revenue and profit performed over time
Revenue
$93.38M
Gross profit
$93.38M
Operating income
-$124.92M
Net income
-$113.68M
Gross margin
100%
Net margin
-121.7%
Zymeworks's revenue has soared by 85% YoY and by 22% from the previous quarter
Zymeworks's gross profit has surged by 85% YoY and by 22% QoQ
The operating margin has soared by 55% YoY and by 26% from the previous quarter
The company's net margin has surged by 51% YoY and by 24% QoQ
Price vs fundamentals
How does ZYME's price correlate with its fundamentals
Growth
What is Zymeworks's growth rate over time
Valuation
What is Zymeworks stock price valuation
P/E
N/A
P/B
2.66
P/S
9.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.64
ZYME's EPS is up by 16% year-on-year and by 7% since the previous quarter
The company's equity fell by 26% YoY and by 4.1% QoQ
ZYME's P/B is 12% above its last 4 quarters average of 2.4 and 3.5% above its 5-year quarterly average of 2.6
Zymeworks's revenue has soared by 85% YoY and by 22% from the previous quarter
The stock's price to sales (P/S) is 62% less than its 5-year quarterly average of 26.9 and 19% less than its last 4 quarters average of 12.5
Efficiency
How efficient is Zymeworks business performance
ZYME's ROS has soared by 55% year-on-year and by 25% since the previous quarter
Zymeworks's return on equity has decreased by 11% YoY
Zymeworks's ROA has decreased by 9% YoY
Dividends
What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZYME.
Financial health
How did Zymeworks financials performed over time
The quick ratio has increased by 39% since the previous quarter but it has declined by 33% year-on-year
The company's current ratio rose by 39% QoQ but it fell by 32% YoY
The company's debt is 94% lower than its equity
The company's debt fell by 27% YoY
The company's equity fell by 26% YoY and by 4.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.